Botulinum Toxin Injections for Neurogenic and Idiopathic Detrusor Overactivity: A Critical Analysis of Results

European Urology

Volumn 50, Issue 4, 2006, Pages 684-710

  Patel, Anand K ^a   Patterson, Jacob M ^a   Chapple, Christopher R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Botox ; Botulinum toxin; Lower urinary tract; Neurogenic idiopathic detrusor overactivity; Overactive bladder; Urgency; Urothelium

Indexed keywords

ANESTHETIC AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; LIDOCAINE; LOCAL ANESTHETIC AGENT; NEUROTOXIN; SEDATIVE AGENT;

ACUTE DISEASE; ASTHENIA; AUTONOMIC DYSFUNCTION; BLADDER ASPIRATION; BLADDER CATHETERIZATION; BLADDER SPHINCTER; CLINICAL TRIAL; CYSTOSCOPE; DETRUSOR DYSSYNERGIA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY EYE; DYSURIA; FLU LIKE SYNDROME; HEMATURIA; HUMAN; IDIOPATHIC DISEASE; INJECTION SITE; INJECTION SITE BURNING; INTERMITTENT CATHETERIZATION; MALAISE; MEDICAL LITERATURE; MICTURITION DISORDER; MUSCLE WEAKNESS; NEUROGENIC BLADDER; PEER REVIEW; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PUBLICATION; RESIDUAL URINE; REVIEW; SELF CARE; SIDE EFFECT; STRESS INCONTINENCE; SYSTEMATIC REVIEW; TACHYPHYLAXIS; URINARY TRACT INFECTION; URINE RETENTION; XEROSTOMIA;

ADULT; BOTULINUM TOXINS, TYPE A; CHILD; HUMANS; INJECTIONS; NEUROMUSCULAR AGENTS; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE;

EID: 33748295503     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.07.022     Document Type: Review

References (77)

1. Smith C.P., Somogyi G.T., and Boone T.B. Botulinum toxin in urology: evaluation using an evidence-based approach. Nat Clin Pract Urol 1 (2004) 31-37
2. Apostolidis A., Dasgupta P., and Fowler C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49 (2006) 644-650
3. Chapple C., and Patel A. Botulinum toxin-new mechanisms, new therapeutic directions?. Eur Urol 49 (2006) 606-608
4. Dykstra D.D., Sidi A.A., Scott A.B., Pagel J.M., and Goldish G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139 (1988) 919-922
5. Schurch B., Schmid D.M., and Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 342 (2000) 665
6. Schurch B., Stohrer M., Kramer G., et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164 (2000) 692-697
7. Reitz A., Stohrer M., Kramer G., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510-515
8. Schurch B., Hauri D., Rodic B., et al. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155 (1996) 1023-1029
9. Haferkamp A., Schurch B., Reitz A., et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 46 (2004) 784-791
10. Schurch B., De Seze M., Denys P., et al. Botulinum toxin A (Botox) in neurogenic urinary incontinence: results from a multicentre randomised, controlled trial. Neurourol Urodyn 23 (2004) 609-610 (abstract no. 151)
11. Schurch B., de Seze M., Denys P., et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (2005) 196-200
12. Schurch B, De Seze M, Denys P, et al. Subgroup analysis to determine impact of patient demographics on urodynamic response to focal administration of botulinum toxin A. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 92).
13. Schulte-Baukloh H., Michael T., Schobert J., Stolze T., and Knispel H.H. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59 (2002) 325-327
14. Riccabona M., Koen M., Schindler M., et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171 (2004) 845-848
15. Schulte-Baukloh H., Michael T., Sturzebecher B., and Knispel H.H. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44 (2003) 139-143
16. Corcos J, Al-Taweel W, Pippi Salle J, Capolicchio G, Jednak R. The treatment of detrusor hyperreflexia using botulinum A toxin in myelomeningocele patients unresponsive to anticholinergic. International Continence Society Annual Meeting, Heidelberg, Germany, Aug. 28-30, 2002 (abstract no. 39).
17. Popat R, Apostolidis A, Fowler C, Dasgupta P. Botulinum toxin works as well in the short term in idiopathic detrusor overactivity (IDO) as in neurogenic detrusor overactivity (NDO). Joint meeting of the International Continence Society (ICS) and the International Uro-Gynaecological Association (IUGA), Paris, France, Aug. 25-27, 2004 (abstract no. 175).
18. Popat R., Apostolidis A., Kalsi V., et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174 (2005) 984-989
19. Chancellor M.B., O'Leary M., Erickson J., et al. Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol 169 (2003) 351 (abstract no. DP50)
20. Sweeney D, O'Leary M, Erickson J, Marx S, Chancellor MB. Safety and efficacy with bladder botulinum toxin in elderly patients. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 453).
21. Sahai A, Khan M, Smith K, Dasgupta P. Botulinum toxin-A for patients with idiopathic detrusor overactivity: early results from a randomised, double-blind, placebo-controlled trial. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 428).
22. Werner M., Schmid D.M., and Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192 (2005) 1735-1740
23. Kuo H.C. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66 (2005) 94-98
24. Schulte-Baukloh H., Weiss C., Stolze T., Sturzebecher B., and Knispel H.H. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 66 (2005) 82-87
25. Hoebeke P, Decaestecker K, Verleyen P, et al. Extended experience with the use of botulinum toxin A in children with non neurogenic voiding dysfunction. ESPU-AAP Joint Conference 2005. Uppsala, Sweden, June 15-18, 2005 (abstract no. 109).
26. Peeren F, Everaert K, Hoebeke P, Decaestecker K. Successive injections of botulinum A toxin (Botox) in paediatric population. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 270).
27. Leippold T., Reitz A., and Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44 (2003) 165-174
28. Harper M., Fowler C.J., and Dasgupta P. Botulinum toxin and its applications in the lower urinary tract. BJU Int 93 (2004) 702-706
29. Maria G., Cadeddu F., Brisinda D., Brandara F., and Brisinda G. Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin. Curr Med Chem 12 (2005) 247-265
30. Grosse J., Kramer G., and Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47 (2005) 653-659
31. Silberstein S.D., and Aoki K.R. Botulinum toxin type A: myths, facts, and current research headache. J Head Face Pain 43 (2003) s1
32. Reitz A., and Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 171 (2004) 804-805
33. Truzzi JC, Bruschini H, Simonetti R, Miguel S. What is the best dose for intravesical botulinum-A toxin injection in overactive bladder treatment? A prospective randomised preliminary study. Joint Meeting of the International Continence Society (ICS) and the International Uro-Gynaecological Association (IUGA), Paris, France, Aug. 25-27, 2004 (abstract no. 520).
34. Gousse A, Tunuguntla HSGR, Rodriguez D, Velazquez D. Dose-finding prospective randomized study to evaluate the efficacy and safety of botulinum-A toxin for refractory idiopathic overactive bladder. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract 254).
35. Radziszewski P., and Borkowski A. Botulinum toxin type A intravesical injections for intractable bladder overactivity. Eur Urol Suppl 1 1 (2002) 134 (abstract no. 526)
36. Del Popolo G, Li Marzi V, Panariello G, Lombardi G. English botulinum toxin-A in the treatment of neurogenic detrusor overactivity. International Continence Society Annual Meeting, Florence, Italy, Oct. 7-9, 2003 (abstract no. 96).
37. Schurch B., Stohrer M., Kramer G., et al. Botulinum toxin-A to treat detrusor hyperreflexia in spinal cord injured patients. Neurourol Urodyn 20 (2001) 521-522 (abstract no. 92)
38. Kuo H.C. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63 (2004) 868-872
39. Karsenty G, Boy S, Reitz A, et al. Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-a prospective randomized study to compare 30 vs. 10 injection sites. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 93).
40. Harper M., Popat R.B., Dasgupta R., Fowler C.J., and Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92 (2003) 325-326
41. Zermann D.H., Ishigooka M., and Schmidt R.A. Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodyn 20 (2001) 412-413 (abstract no. 27)
42. Kennelly M.J., and Kang J. Botulinum-A toxin injections as a treatment for refractory detrusor hyperreflexia. Top Spinal Cond Inj Rehabil 8 (2003) 46-53
43. Wyndaele J.J., and Van Dromme S.A. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40 (2002) 599-600
44. Schulte-Baukloh H., Weiss C., Stolze T., et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48 (2005) 984-990
45. Karsenty G, Lindemann G, Reitz A, et al. The effect of repeated injections of botulinum toxin type A on the efficacy of the treatment of neurogenic overactive bladder and the urinary bladder. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 242).
46. Rackley R., and Abdelmalak J. Urologic applications of botulinum toxin therapy for voiding dysfunction. Curr Urol Rep 5 (2004) 381-388
47. Pistolesi D., Selli C., Rossi B., and Stampacchia G. Botulinum toxin type B for type A resistant bladder spasticity. J Urol 171 (2004) 802-803
48. Hirst G, Wareham K, Emery S, Lucas M. Failure of botulinum toxin type B in the treatment of the refractory overactive bladder. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 432).
49. Ghei M., Maraj B.H., Miller R., et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 174 (2005) 1873-1877
50. Dykstra D., Enriquez A., and Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 14 (2003) 424-426
51. Schurch B., and Corcos J. Botulinum toxin injections for paediatric incontinence. Curr Opin Urol 15 (2005) 264-267
52. Grosse J., Kramer G., Schurch B., and Stohrer M. Repeat detrusor injections of botulinum A toxin in patients with neurogenic lower urinary tract dysfunction do not cause increased drug tolerance. Neurourol Urodyn 21 (2002) 386-387 (abstract no. 79)
53. Giannantoni A., Mearini E., Di Stasi S.M., et al. New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56 (2004) 79-87
54. ®) in neurogenic urinary incontinence. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 261).
55. Loch A., Loch T., Osterhage J., Alloussi S., and Stockle M. Botulinum-A toxin detrusor injections in the treatment of non-neurologic and neurologic cases of urge incontinence. Eur Urol Suppl 2 1 (2003) 172 (abstract no. 678)
56. Patki P, Arumungam K, Hamid R, Shar PJR, Craggs M. Day case treatment of resistant neurogenic detrusor overactivity, following spinal cord injury. British Association of Urological Surgeons Annual Meeting, Glasgow, UK, June 27-July 1, 2005 (abstract no. 62).
57. Giannantoni A, Nardicchi V, Di Stasi S, et al. Botulinum A toxin intravesical injections reduce nerve growth factor bladder tissue content in patients affected by neurogenic detrusor overactivity. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 221).
58. Chancellor M.B., and Smith C.P. A single surgeon's six-year experience with botulinum toxin injection into the bladder and urethra. J Urol 171 (2004) 138 (abstract no. 517)
59. Smith C.P., Nishiguchi J., O'Leary M., Yoshimura N., and Chancellor M.B. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65 (2005) 37-41
60. Bagi P., and Biering-Sorensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38 (2004) 495-498
61. Giannantoni A., Di Stasi S.M., Stephen R.L., et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 172 (2004) 240-243
62. Kessler T.M., Danuser H., Schumacher M., Studer U.E., and Burkhard F.C. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn 24 (2005) 231-236
63. Toh K, Tow A, Consigliere D. Botulinum toxin type A for refractory detrusor overactivity in patients with spinal cord injuries in Asia: preliminary results. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 433).
64. Rapp D.E., Lucioni A., Katz E.E., et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63 (2004) 1071-1075
65. Schumacher S., Haferkamp A., and Muller S.C. Therapy of neurogenic and non neurogenic detrusor overactivity with detrusor-injections of botulinum-a toxin and continent vesicostomy. Eur Urol Suppl 2 (2003) 141 (abstract no. 554)
66. Dykstra D.D., Pryor J., and Goldish G. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report. Arch Phys Med Rehabil 84 (2003) 1399-1400
67. Schmid D., John H., Hauri D., and Schurch B. Experience of 100 cases treated with botulinum-A toxin injections into the detrusor muscle for overactive bladder refractory to anticholinergics. Eur Urol Suppl 4 3 (2005) 142 (abstract no. 559)
68. Schmid D.M., Schurch B., John H., and Hauri D. Botulinum toxin injections to treat overactive bladder. Eur Urol Suppl 3 2 (2004) 131 (abstract no. 516)
69. Kalsi V, Popat R, Odyemi I, et al. A cost effectiveness model for botulinum neurotoxin type A (BoNT/A) in the treatment of patients with detrusor overactivity: preliminary results. British Association of Urological Surgeons Annual Meeting, Glasgow, UK, June 27-July 1, 2005 (abstract no. 61).
70. Abdelmalak JB, Rackley RR, Vasavada SP, et al. Botulinum A toxin (Botox) injection for the treatment of refractory overactive bladder. American Urological Association Annual Meeting, San Francisco, CA, USA, May 8-13, 2004 (abstract no. 531).
71. Werner M, Schmid D, Schurch B, Schuessler B. Efficacy of botulinum-A toxin in the treatment of refractory overactive bladder syndrome: preliminary results of a prospective non-randomized study. International Continence Society Annual Meeting, Paris, France, Aug. 25-27, 2004 (abstract no. 168).
72. Fowler C., Popat R., Apostolidis A., et al. Intradetrusor injections of botulinum A toxin to treat severe detrusor overactivity. J Neurol Neurosurg Psychiatry 75 (2004) 1216 (abstract no. 846)
73. Keppenne V, Gaspard Y, Mathantu B, Sanjurjo S, de Leval J. Detrusor injection of botulinum A toxin for idiopathic overactive bladder syndrome: clinical and urodynamic evaluation. International Continence Society Annual Meeting, Montreal, Canada, Aug. 31-Sep. 2, 2005 (abstract no. 498).
74. Mustafa AW, Small DR, Rajkumar GN, Conn IG. A quantitative assessment of the effect of botulinum toxin type A on voiding detrusor contractility. British Association of Urological Surgeons Annual Meeting, Glasgow, UK, June 27-July 1, 2005 (abstract no. 59).
75. Rajkumar G.N., Small D.R., Mustafa A.W., and Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96 (2005) 848-852
76. Flynn M.K., Webster G.D., and Amundsen C.L. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 172 (2004) 2316-2320
77. Verleyen P., Hoebeke P., Raes A., Van Laecke E., and Vande Walle J. The use of botulinum toxin A in children with a non-neurogenic overactive bladder: a pilot study. BJU Int 93 Suppl 2 (2004) 96 (abstract no. 168) from the European Society of Paediatric Urology Congress in Regensburg, Germany, April 21-24, 2004